IGHE and allergic disease: The post hoc analysis of VOYAGE [58] evaluated its efficacy in patients aged 6–11 years with type 2 asthma independently from the evidence of allergy-driven asthma (serum total IgE ≥ 30 IU/mL and ≥1 perennial aeroallergen-specific IgE ≥ 0.35 kU/L).